Bayer announced last week that the UK’s MHRA has authorised its 52mg levonorgestrel releasing intrauterine system Mirena for extended use up to eight years for contraception in the UK.
Novartis recently announced that it has received approval from the US FDA for commercial manufacturing of Pluvicto at its new large-scale, state-of-the-art radioligand therapy (RLT) manufacturing facility in Indianapolis, Indiana, United States.
Cornell Stamoran, Vice President, Strategy and Government Affairs, Catalent and Matt Mollan, Vice President Operations at Catalent explore the complexities of manufacturing orphan drugs in product development for our EPM Magazine.
The National Institute for Health and Care Excellence (NICE) has issued its Final Draft Guidance (FDG) recommending empagliflozin (Jardiance) as an option for the treatment of eligible adults with chronic kidney disease.
The U.S. Food and Drug Administration (FDA) and the Medicines and Healthcare products Regulatory Agency have approved Eli Lilly and Company's Zepbound (Mounjaro) (tirzepatide) injection
Cristina Grigore, Technical Proposals Manager, Lonza Ltd discusses the evolving landscape for the role CDMOs play as essential partners with biotech for developing new medicines.
Pete Lomas, Managing Consultant at Broughton, a scientific consultancy and contract research organisation, discusses how manufacturers can design vapes to improve their chances of MAA approval.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Jardiance (empagliflozin) for the treatment of adults with chronic kidney disease (CKD), Boehringer Ingelheim and Eli Lilly and Company announced.
MGC Pharma's breakthrough in epilepsy treatment with CannEpil is now available in the UK. This high-CBD, low-THC formulation is part of a pioneering approach to refractory epilepsy treatment. Learn how MGC Pharma is transforming patient care a
Prof. Andy Whiting, Nevrargenics, responds to the lack of translational funding for the biotech industry, and what more needs to be done to close the gap between drug development and clinical trials.
